Business, energy, technology, markets and global industry news from Business News Today

Hamburg

PharmaDeviceNews Hamburg
Prime Medicine's PM647 has received FDA clearance to enter first-in-human testing as the company advances a one-time Prime Editing therapy targeting the genetic cause of alpha-1 antitrypsin deficiency. Representative image.
Pharma & Biotech

Dyno Therapeutics reports 152-fold brain transduction improvement and new immune-evasive AAV capsid data at ESGCT 2026

Dyno Therapeutics reports 152-fold higher brain transduction than AAV9 in primates, plus new muscle and antibody-evasive capsid data.

Read More